The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

1.

Fuente:
https://www.sciencedirect.com/science/article/pii/S0924857920301047

Resguardo:
https://archive.is/XKJqa



2. La versión PDF está disponible en el siguiente enlace:
https://drive.google.com/file/d/1GX6b0Z1zpPyISUo7tjQCYu01K0higFdh/view?usp=sharing